title: Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European group for blood and marrow transplantation.
abstract: Protocols for the prevention of infections after allogeneic or autologous hemopoietic stem cell transplantations are usual. A questionnaire was sent out to the members of the European Group for Bone and Marrow Transplantation (EBMT) in the spring of 1999. A total of 308 questionnaires from 180 centers were returned. Both allogeneic and autologous transplantation was reported from 128 centers, and allogeneic or autologous transplantation alone from four and 48 centers, respectively. Hemopoietic stem cell transplantation is still a domain of university hospitals. Intensive measures of isolation are usual. Allotransplantation is commonly performed in single rooms with HEPA-filtered air on special wards. However, even in the autologous setting, extensive measures of isolation are commonly used. This observation could be explained by historical developments and by the fact that nearly all centers for allogeneic transplantation perform both allogeneic and autologous transplantations, and thus similar measures are used in both settings. Other measures are usual but heterogeneous due to lack of clinical trials in this field. Drug prophylaxis during transplantation is mostly carried out with quinolones, TMP/SMZ, fluconazole, acyclovir, and pentamidine. Differences in drug prophylaxis after engraftment and in the use of different venous accesses do reflect the requirements after engraftment and discharge of patients from the transplant unit. The intensity of measures in autologous stem cell reinfusion does not reflect the development during the last decade. For cost effectiveness and convenience, it is necessary to abolish senseless measures. It is necessary to investigate anti-infectious strategies separately for allogeneic transplantation and other modalities of anti-cancer treatment in future.
authors.affiliation: Bone Marrow Transplantation Centre, University-Hospital Eppendorf, Hamburg, Germany. william.krueger@medizin.uni-halle.de
authors.forename: W H
authors.initials: WH
authors.lastname: Krüger
authors.forename: R J
authors.initials: RJ
authors.lastname: Hornung
authors.forename: B
authors.initials: B
authors.lastname: Hertenstein
authors.forename: W V
authors.initials: WV
authors.lastname: Kern
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
authors.forename: A R
authors.initials: AR
authors.lastname: Zander
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use; D003140:Communicable Disease Control / Q000379:methods*; D003141:Communicable Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D003625:Data Collection; D019468:Disease Management; D005060:Europe; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000592:standards; D006801:Humans; D006920:Hygiene; D017053:Infection Control / Q000379:methods; D009747:Nutritional Physiological Phenomena; D010356:Patient Isolation; D013242:Sterilization
chemical_list: D000890:Anti-Infective Agents